Long-term electrocardiographic studies of patients with Duchenne's muscular dystrophy.

1988 ◽  
Vol 29 (3) ◽  
pp. 295-300 ◽  
Author(s):  
Suguru MATSUOKA ◽  
Yuji AKITA ◽  
Satomi KAWAHITO ◽  
Atsuko NISHIOKA ◽  
Yoko MIKI ◽  
...  
Keyword(s):  
Muscular Dystrophy ◽  
Duchenne's Muscular Dystrophy

scholarly journals Long-term observation of cardiac function in Duchenne's muscular dystrophy. Evaluation using systolic time intervals and echocardiography.

1990 ◽  
Vol 31 (5) ◽  
pp. 585-597 ◽  
Author(s):  
Toshinori UTSUNOMIYA ◽  
Hideki MORI ◽  
Noritoshi SHIBUYA ◽  
Yasuhiko OKU ◽  
Shuzo MATSUO ◽  
...  
Keyword(s):  
Muscular Dystrophy ◽  
Cardiac Function ◽  
Systolic Time Intervals ◽  
Time Intervals ◽  
Systolic Time ◽  
Long Term Observation ◽  
Duchenne's Muscular Dystrophy

Decline in Respiratory Function and Experience with Long-Term Assisted Ventilation in Advanced Duchenne's Muscular Dystrophy

CHEST Journal ◽  
1990 ◽  
Vol 97 (4) ◽  
pp. 884-889 ◽  
Author(s):  
Ahmet Baydun ◽  
Irene Gilgoff ◽  
William Prentice ◽  
Michael Carlson ◽  
D. Armin Fischer
Keyword(s):  
Muscular Dystrophy ◽  
Respiratory Function ◽  
Assisted Ventilation ◽  
Duchenne's Muscular Dystrophy

Long-term Nasal Intermittent Positive Pressure Ventilation in Advanced Duchenne's Muscular Dystrophy

CHEST Journal ◽  
1994 ◽  
Vol 105 (2) ◽  
pp. 445-448 ◽  
Author(s):  
Andrea Vianello ◽  
Matteo Bevilacqua ◽  
Vittorino Salvador ◽  
Claudio Cardaioli ◽  
Ezio Vincenti
Keyword(s):  
Muscular Dystrophy ◽  
Positive Pressure Ventilation ◽  
Intermittent Positive Pressure Ventilation ◽  
Positive Pressure ◽  
Duchenne's Muscular Dystrophy

scholarly journals A CASE REPORT ON THE MANAGEMENT OF DUCHENNE’S MUSCULAR DYSTROPHY (DMD) WITH MATRA BASTI

2021 ◽  
Vol p5 (02) ◽  
pp. 2750-2755
Author(s):  
Sharayu Kachole ◽  
Niranjan Rao ◽  
Padmakiran C
Keyword(s):  
Muscular Dystrophy ◽  
Treatment Protocol ◽  
Dystrophin Gene ◽  
Shoulder Girdle ◽  
Recessive Mutation ◽  
Multiple Systems ◽  
Before And After ◽  
Dual Action ◽  
Duchenne's Muscular Dystrophy

Duchenne’s Muscular Dystrophy (DMD) is the most common x-linked disorder in children presenting in early childhood due to recessive mutation of the dystrophin gene. It is characterized by progressive weak-ness in hip and shoulder girdle muscles beginning by age 5. Although there is no absolute cure for DMD, therapies can delay the onset or slow down the progression of disease. Survival beyond the age of 30 years is rare due to the severe chronic complication involving multiple systems. Serum Creatine Phosphokinase (CPK) level determination is the most specific objective parameter for the diagnosis and assessment of se-verity of Muscular Dystrophy (MD). Based on the presentation of DMD, it can be diagnosed as Mamsavru-ta Vatal leading to Mamsa Dhatu Upashoshana which is the consequence of Beejabhagavikruti. There will be continuous destruction of Dhatu leading to Vataprakopa again. Hence, the line of management is con-trolling the Vata and preventing the destruction. The best treatment for it which has this dual action is Mat-ra Basti. With this basic concept, a male child of 10 years diagnosed as Mamsavruta Vata was treated with Matra Basti using Dhanwantara Taila 10 ml/day for about 9 months. As there was associated Sama Do-shavastha, Agnichikitsa Lepa was advised for 7 days initially. The treatment showed significant reduction in the level of CPK tested before and after the treatment. Hence, the treatment protocol followed can be taken up for further research and can prove with evidence that, it can be effectively practiced in the man-agement of DMD. The long-term benefit, improvement in disease, quality of life can be accessed through the research with long term follow-ups.

scholarly journals Dental pulp stem cells can improve muscle dysfunction in animal models of Duchenne muscular dystrophy

2021 ◽  
Vol 12 (1) ◽  
Author(s):  
Yuko Nitahara-Kasahara ◽  
Mutsuki Kuraoka ◽  
Posadas Herrera Guillermo ◽  
Hiromi Hayashita-Kinoh ◽  
Yasunobu Maruoka ◽  
...  
Keyword(s):  
Stem Cells ◽  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Dental Pulp ◽  
Systemic Treatment ◽  
Dental Pulp Stem Cells ◽  
Mri Findings ◽  
Systemic Injection ◽  
Therapeutic Benefits

Abstract Background Duchenne muscular dystrophy (DMD) is an inherited progressive disorder that causes skeletal and cardiac muscle deterioration with chronic inflammation. Dental pulp stem cells (DPSCs) are attractive candidates for cell-based strategies for DMD because of their immunosuppressive properties. Therefore, we hypothesized that systemic treatment with DPSCs might show therapeutic benefits as an anti-inflammatory therapy. Methods To investigate the potential benefits of DPSC transplantation for DMD, we examined disease progression in a DMD animal model, mdx mice, by comparing them with different systemic treatment conditions. The DPSC-treated model, a canine X-linked muscular dystrophy model in Japan (CXMDJ), which has a severe phenotype similar to that of DMD patients, also underwent comprehensive analysis, including histopathological findings, muscle function, and locomotor activity. Results We demonstrated a therapeutic strategy for long-term functional recovery in DMD using repeated DPSC administration. DPSC-treated mdx mice and CXMDJ showed no serious adverse events. MRI findings and muscle histology suggested that DPSC treatment downregulated severe inflammation in DMD muscles and demonstrated a milder phenotype after DPSC treatment. DPSC-treated models showed increased recovery in grip-hand strength and improved tetanic force and home cage activity. Interestingly, maintenance of long-term running capability and stabilized cardiac function was also observed in 1-year-old DPSC-treated CXMDJ. Conclusions We developed a novel strategy for the safe and effective transplantation of DPSCs for DMD recovery, which included repeated systemic injection to regulate inflammation at a young age. This is the first report on the efficacy of a systemic DPSC treatment, from which we can propose that DPSCs may play an important role in delaying the DMD disease phenotype.

Oral bisphosphonate treatment in patients with Duchenne muscular dystrophy on long term glucocorticoid therapy

2020 ◽  
Vol 30 (7) ◽  
pp. 599-610
Author(s):  
Cuixia Tian ◽  
Brenda L. Wong ◽  
Lindsey Hornung ◽  
Jane C. Khoury ◽  
Irina Rybalsky ◽  
...  
Keyword(s):  
Duchenne Muscular Dystrophy ◽  
Muscular Dystrophy ◽  
Glucocorticoid Therapy ◽  
Bisphosphonate Treatment ◽  
Oral Bisphosphonate
Sign in / Sign up

Export Citation Format

Share Document